Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Extrahepatic cholangiocarcinoma (perihilar and distal), drawn from the whole corpus: 80 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most perihilar tumours are unresectable at presentation, and half of resections leave microscopic disease.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Biliary obstruction and cholangitis, not the cancer's growth, often end treatment.
No targeted therapy exists for the KRAS-mutant majority.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
OS 14.
A milestone in how this cancer is treated.
3-year overall survival 77.
Confirmed ORR by independent central review 41.
OS 12.